Status:
RECRUITING
Samsca Post-marketing General Drug Use-results Survey in Patients with Hyponatremia in SIADH
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.
Conditions:
Antidiuretic Hormone, Inappropriate Secretion
Eligibility:
All Genders
Brief Summary
The purpose of this study is to confirm the safety of tolvaptan in patients with hyponatremia in syndrome of inappropriate antidiuretic hormone secretion (SIADH) in Japan
Eligibility Criteria
Inclusion
- Subjects with a definite diagnosis of SIADH in reference to "Diagnostic and Treatment Manual of the Hypersecretion of Vasopressin (SIADH), Revised in 2018"
Exclusion
- \-
Key Trial Info
Start Date :
March 29 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2030
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04790175
Start Date
March 29 2021
End Date
January 1 2030
Last Update
March 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pharmacovigilance Department
Osaka, Osaka, Japan, 540-0021